Journal
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Volume 91, Issue 6, Pages -Publisher
WILEY
DOI: 10.1111/sji.12875
Keywords
immunotherapy; neoantigen; peptide vaccine; tumour antigen; tumour vaccine
Categories
Funding
- Natural Science of Foundation of Zhejiang Province [LY15H160037] Funding Source: Medline
- National Major Scientific and Technological Special Project for 'Significant New Drugs Development' [2014ZX09102041-009] Funding Source: Medline
- Science Technology Department of Zhejiang Province [2014C03041-1] Funding Source: Medline
Ask authors/readers for more resources
In recent years, relying on the human immune system to kill tumour cells has become an effective means of cancer treatment. The development of peptide vaccines, which not only break the immune tolerance of a tumour but also attack malignant cells via specific antitumour immunity, has received increased attention in tumour immunization therapy due to their safety and easy preparation. The use of large-scale sequencing technology enables the continuous discovery of new tumour antigens. With improved accuracy of epitope prediction by computer simulation and the usage of a tetramer assay, cytotoxic lymphocyte epitopes can be screened and identified more easily. Transmembrane peptide and nanoparticle technologies promote more effective intake and delivery of antigens. Consequently, considerable evolution from universal to personalized peptide vaccines has taken place, and such vaccines induce an efficient and specific immune response targeting tumour neoantigens. Recently, genomic analysis and bioinformatics approaches have greatly facilitated the breakthrough of personalized peptide vaccines targeting neoantigens, resulting in a renewed interest in this field. Further, the combination of tumour peptide vaccines with checkpoint blockades may improve patient outcomes. In this review, we discuss the development of tumour peptide vaccines and the new technological progress, from universalization to personalization, to highlight the substantial promise of tumour peptide vaccines in clinical cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available